Back to discover
Disease
Carcinoma of liver and intrahepatic biliary tract
Late-stage therapeutic development
Also known as carcinoma of liver and IBT, liver and intrahepatic bile duct carcinoma, liver and intrahepatic biliary tract cancer, liver and intrahepatic biliary tract carcinoma+11 more
carcinoma of liver and IBT, liver and intrahepatic bile duct carcinoma, liver and intrahepatic biliary tract cancer, liver and intrahepatic biliary tract carcinoma, primary liver carcinoma, hepatocellular carcinoma plus intrahepatic cholangiocarcinoma, cancer of liver, cancer of liver and intrahepatic biliary tract, cancer of the liver, cancer of the liver and intrahepatic biliary tract, carcinoma of liver, hepatic cancer, liver and intrahepatic bile duct cancer, liver carcinoma, liver/hepatobiliary cancer.
24
Clinical trials
12
Associated genes
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 5 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
- Q1 2028A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma
- Q4 2028A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)
- Q1 2029A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)
- Q1 2030A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20282026-07-28
Upcoming trial readoutHigh impact
Results expected Q1 20292026-07-10
Clinical MilestonesView all 13Hide
Results expected
- 2026-07-28A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)Results expected Q4 2028
- 2026-07-10A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)Results expected Q1 2029
- 2026-03-10A Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Results expected Q1 2030
- 2026-02-17IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)Results expected Q1 2027
- 2026-01-12A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic MelanomaResults expected Q1 2028
Recently completed
- 2026-06-29A Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus InfectionCompleted
- 2026-06-17A Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal CancerCompleted
- 2026-02-09Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular CarcinomaCompleted
- 2026-01-20TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint InhibitorCompleted
- 2025-12-31A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced Hepatocellular CarcinomaCompleted
Other updates
- 2028-04-30A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Compare the Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Surgical ResectionWithdrawn
- 2025-10-31Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.Terminated
- 2025-10-13Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung CancerTerminated
+5 more in the activity timeline below
Activity timeline13
- 2028-04-30ClinicalA Randomized, Double-blind, Placebo-controlled Phase 3 Study to Compare the Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Surgical ResectionWithdrawn
- 2026-07-28ClinicalA Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)Results expected Q4 2028
- 2026-07-10ClinicalA Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)Results expected Q1 2029
- 2026-06-29ClinicalA Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus InfectionCompleted
- 2026-06-17ClinicalA Phase II Study of Temozolomide, Cisplatin and Nivolumab in MMR-Proficient Colorectal CancerCompleted
- 2026-03-10ClinicalA Phase Ib/III Randomized, Multicenter, Global Study of Volrustomig Plus Casdatifan or Volrustomig Monotherapy Versus Nivolumab Plus Ipilimumab as First-line Treatment for Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Results expected Q1 2030
- 2026-02-17ClinicalIDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)Results expected Q1 2027
- 2026-02-09ClinicalRandomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular CarcinomaCompleted
- 2026-01-20ClinicalTiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint InhibitorCompleted
- 2026-01-12ClinicalA Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic MelanomaResults expected Q1 2028
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
16
6
Late-stage studies
Recently completed
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
carcinoma of liver and IBT, liver and intrahepatic bile duct carcinoma, liver and intrahepatic biliary tract cancer, liver and intrahepatic biliary tract carcinoma, primary liver carcinoma, hepatocellular carcinoma plus intrahepatic cholangiocarcinoma, cancer of liver, cancer of liver and intrahepatic biliary tract, cancer of the liver, cancer of the liver and intrahepatic biliary tract, carcinoma of liver, hepatic cancer, liver and intrahepatic bile duct cancer, liver carcinoma, liver/hepatobiliary cancer
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.